1 Colditz GA, "Weight gain as a risk factor for clinical diabetes mellitus in women" 122 : 481-486, 1995
2 Park Y, e, "Prevalence of diabetes and IGT in Yonchon County, South Korea" 18 : 545-548, 1995
3 Scheen AJ, "Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus" 75 : 33-59, 2015
4 Korean Food and Drug Administration, "Pharmaceuticals and Medical Devices Agency(PMDA) “SGLT2 inhibitors” permitted articles"
5 Hamren B, "Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment" 84 : 228-235, 2018
6 Silvio E, "Management of Hyperglycemia in Type 2 Diabetes 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes" 38 (38): 140-149, 2015
7 Bakris GL, "INVEST Investigators. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study" 44 : 637-642, 2004
8 European Medicines Agency, "Guideline on clinical investigation of medicinal products in the treatments or prevention of diabetes mellitus"
9 Korean Food and Drug Administration, "Forxiga permitted articles"
10 YANG W, "Efficacy and safety of dapagliflozin in Asian patients : A pooled analysis" 9 (9): 787-789, 2017
1 Colditz GA, "Weight gain as a risk factor for clinical diabetes mellitus in women" 122 : 481-486, 1995
2 Park Y, e, "Prevalence of diabetes and IGT in Yonchon County, South Korea" 18 : 545-548, 1995
3 Scheen AJ, "Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus" 75 : 33-59, 2015
4 Korean Food and Drug Administration, "Pharmaceuticals and Medical Devices Agency(PMDA) “SGLT2 inhibitors” permitted articles"
5 Hamren B, "Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment" 84 : 228-235, 2018
6 Silvio E, "Management of Hyperglycemia in Type 2 Diabetes 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes" 38 (38): 140-149, 2015
7 Bakris GL, "INVEST Investigators. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study" 44 : 637-642, 2004
8 European Medicines Agency, "Guideline on clinical investigation of medicinal products in the treatments or prevention of diabetes mellitus"
9 Korean Food and Drug Administration, "Forxiga permitted articles"
10 YANG W, "Efficacy and safety of dapagliflozin in Asian patients : A pooled analysis" 9 (9): 787-789, 2017
11 ACCORD Study group, "Effects of intensive blood-pressure control in type 2 diabetes mellitus" 362 (362): 1575-1585, 2010
12 Ptaszynska A, "Effects of Dapagliflozin on Cardiovascular Risk Factors" 3 : 125-, 2013
13 Bailey CJ, "Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial" 375 (375): 2223-2233, 2010
14 Korean Diabetes Association, "Diabetes fact sheet in Korea"
15 Plosker GL, "Dapagliflozin : A Review of Its Use in Patients with Type 2Diabetes" 74 : 2191-2109, 2014
16 World Heart Federation., "Cardiovascular Risk Factors"
17 Korean Diabetes Association, "2015 Treatment guideline for diabetes (5th edition)"
18 Kosuke Tauchi., "10 deaths reported following use of newly marketed diabetes drugs"